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Abstract 
Fatty acid synthase (FASN) is commonly overexpressed in prostate cancer and 
associated with tumour progression.  FASN is responsible for de novo synthesis of 
the fatty acid palmitate; the building block for protein palmitoylation. Recent work has 
suggested that alongside its established role in promoting cell proliferation FASN 
may also promote invasion. We now find depletion of FASN expression increases 
prostate cancer cell adhesiveness, impairs HGF-mediated cell migration and 
reduces 3D invasion. These changes in motility suggest that FASN can mediate 
actin cytoskeletal remodelling; a process known to be downstream of Rho family 
GTPases.  Here, we demonstrate that modulation of FASN expression specifically 
impacts on the palmitoylation of the atypical GTPase RhoU. Impaired RhoU activity 
in FASN depleted cells leads to reduced adhesion turnover downstream of paxillin 
serine phosphorylation, which is rescued by addition of exogenous palmitate. 
Moreover, canonical Cdc42 expression is dependent on the palmitoylation status of 
RhoU. Thus we uncover a novel relationship between FASN, RhoU and Cdc42 that 
directly influences cell migration potential. These results provide compelling 
evidence that FASN activity directly promotes cell migration and supports FASN as a 
potential therapeutic target in metastatic prostate cancer.  
 
  
Introduction 
The five-year survival rate of patients with localized prostate cancer is approximately 
98% which drops drastically to 28% if the prostate cancer has spread to other parts 
of the body (1). Despite the current efforts of early detection, 10-20% of cases 
present with widespread metastasis at the time of diagnosis (2). Thus there is an 
urgent need to understand the molecular drivers of prostate cancer invasion for the 
development of novel biomarkers of aggressiveness and therapeutics.  
 
A prerequisite of metastasis is the adoption of a migratory phenotype (3). Cell 
migration relies on the continuous reorganisation of the actin cytoskeleton, which can 
be triggered via the activity of Rho family GTPases (4). Rho GTPases are frequently 
post-translationally modified by lipids via palmitoylation and/or prenylation  which 
promotes specific subcellular localization (4). In addition to changes in motile 
properties it has long been recognised that cancer cells exhibit alterations in their 
metabolic activity. This metabolic reprogramming increases the production of 
metabolic intermediates required to support rapid proliferation (5). Increased 
lipogenesis is recognised as a major hallmark for tumour progression with cancer 
cells switching to dependence on de novo fatty acid (FA) synthesis (5).  
 
The main metabolic enzyme responsible for the generation of FA in the cell is Fatty 
Acid Synthase (FASN) (6) which is consistently overexpressed in prostatic tumours 
(7, 8). Indeed, changes in FASN expression are an early event in the development of 
prostate cancer (7) and can be identified as the primary source of palmitate in cancer 
cells. FASN has been identified as an important enzyme and candidate oncogene as 
far back as 2009. However,  the emphasis has been mainly on FASN activity to 
promote cellular proliferation (6). Some more recent studies also suggest that FASN 
might play a role in promoting cellular migration, where reduced expression of FASN 
has been associated with impaired cell migration in prostate and colorectal cancer 
cells (9, 10). Indeed, FASN was indirectly associated with prostate cancer migration 
via degradation of the androgen receptor (11). However, none of these studies 
focussed on intrinsic migration and the potential downstream pathways that might 
mediate this response. Importantly metastasis initiating cells upregulate their FA 
availability via the CD36 receptor (12) and this event is required to drive distal site 
colonisation. However, the molecular mechanisms through which increased levels of 
intracellular FA drive metastasis have yet to be elucidated.  We therefore sought to 
understand whether the activity of FASN is essential for prostate cancer cellular 
migration/invasion and to elucidate the specific molecular pathways that might be 
impacted when the availability of intracellular palmitate is manipulated through 
changes in FASN expression levels.  
  
Materials and Method 
Antibodies and reagents  
Rabbit anti-RhoU (Wrch1) from Abcam. Mouse anti-paxillin and anti-FASN from BD 
Biosciences, rabbit anti-phospho-paxillin S273 (272) from Invitrogen, mouse anti-
GFP from Roche, rabbit anti- HSP90 from Santa-Cruz and mouse anti-vinculin from 
Sigma-Aldrich. HRP-conjugated secondary antibodies from DAKO.  
 
Cell culture 
PC3 prostate cancer cells (ETCC) were grown in RPMI 10% FBS (Sigma-Aldrich) 
and 100 U/ml penicillin/streptomycin. The 1542-CPTX (13) primary prostate cancer 
cell line kindly gifted by Prof. John Masters (UCL), was  grown in KSFM 
supplemented with 10% FBS, 0.1 mg/ml bovine pituitary extract, 5 ng/ml EGF and 
100 U/ml penicillin/streptomycin. PC3 and 1542 cells were transiently transfected 
using ViaFect™ (Promega). HEK-293 cells (ETCC) were grown in complete DMEM 
(Sigma-Aldrich) supplemented with 10% FCS (Sigma-Aldrich) and 100 U/ml 
penicillin/streptomycin and transfected by calcium-phosphate transfection according 
to the manufacturer’s protocol (Sigma-Aldrich).  
 
siRNA and shRNA transfection 
PLKO.1 lentiviral constructs containing two different shRNA sequences were 
generated by the RNAi Consortium (Broad Institute Cambridge) see supplemental 
methods for all sequences. Supernatant containing lentivirus was used to infect 
target cells in the presence of 5ug/ml polybrene. Cells were selected with 2ug/ml 
puromycin (Sigma). For transient knockdown cells were transfected with siRNA 
oligonucleotides using RNAiMax (ThermoFisher). shFASN A3(CATGGAGCGTAT 
CTGTGAGAA),shFASNA4 (CGAGAGCACCTTTGATGACAT), shControl 
(ACAACAGCCACAACGTCTATA).  Control siRNA oligo (AATTCTCCGAA 
CGTGTCACGT) was purchased from Qiagen. The RhoU SMARTpool siRNA oligo 
(#1- GTACTGCTGTTTCGTATGA, #2- GAACGTCAGTGAGAAATGG, #3- 
CAGAGAAGATGTCAAAGTC, #4- AAGCAGGACTCCAGATAAA) was purchased 
from Dharmacon 
 
Adhesion assay 
Cells were seeded in 96 well plates pre-coated with either 10 μg/ml Matrigel (BD 
Biosciences) or type I Collagen (Corning). After 60 min at 37°C, the cells were 
washed twice with PBS, and incubated in 500 μg/ml methylthiazoletetrazolium (MTT; 
Sigma). and solubilized using DMSO. Absorbance at 540 nm was measured using a 
plate reader (Perkin Elmer). 
 
Migration Assay  
Cells were treated with 20 mM Hepes and 20 ng/ml HGF and placed on a heated 
(37°C) stage of an Olympus IX71 microscope. Images were collected using a Retiga 
SRV CCD camera, every 5 mins for 16 h using Image-Pro Plus software. All the 
acquired time-lapse sequences were displayed as a movie and cells were tracked 
using ImageJ (14). Mathematical analysis was carried out using Mathematica 6.0™ 
notebooks (14) where the mean cell migration speed is calculated for each cell and 
this data is used to calculate a mean cell migration speed for each population. 
Statistical significance was calculated using ANOVA accepted for p ≤ 0.05.  
 
Invasion Assay 
For the inverted invasion assay cells were mixed with type I collagen and then 
centrifuged to the bottom of a 96 well plate and incubated for 24 h at 37˚C in growth 
medium. Cells were fixed and stained with formaldehyde: Hoechst. This experiment 
was performed three separate times. In each experiment 18 wells were seeded with 
control cells and 18 wells were seeded with ShRNA cells. Any wells damaged during 
the processing for quantification were discarded from the analysis. The plates were 
imaged on the A1R confocal microscope where a series of z-stacked images were 
taken. Thresholding and particle analysis of cells was performed on both planes. The 
number of cells (as defined by a particles score in Velocity) measured at 50 
micrometres was compared to the number of cells at the bottom of the well (as 
defined by a particles score in Velocity) to get a relative invasion percentile. Each dot 
on the graph represents one well and records the % of cells in that well that were 
able to invade over 50um in distance.  A mean % invasion percentile was calculated 
for each condition and a Students t-test used to calculate the significant difference 
between the means. Relative % of invasion was calculated by comparing images 
taken from the bottom of the well against invasion at 50 microns using particle 
analysis software. See supplemental data for extended experimental and 
quantification details.  
 
Immunofluorescence and image analysis 
Cells were seeded onto Matrigel (10 μg/ml; BD biosciences)-coated coverslips, fixed 
in 4% paraformaldehyde and permeabilised with 0.2% Triton X-100. For F-actin 
staining, cells were incubated with either TRITC- or Alexa fluor 488-conjugated 
phalloidin (Invitrogen). For detection of paxillin, antibodies were incubated for 2 h at 
room temperature. Cells were then washed with PBS before incubation with Alexa 
fluor 647 or 488-conjugated secondary antibodies (Invitrogen) and phalloidin. 
Stained cells were imaged using either an Olympus IX71 microscope with or a Zeiss 
LSM510 confocal laser-scanning microscope and the accompanying LSM510 
software. Focal adhesion number and length were quantified using Image J software 
(NIH). Cells were scored positive for prominent focal adhesions if more than 10 
paxillin positive adhesions were readily visible at the cell periphery.  
 
Immunoblotting and immunoprecipitation 
Prostate tissue samples (kindly donated by Dr Jonathan Morris) from patients with 
benign prostatic hyperplasia (G36, G40 and H5) or prostate cancer (F2, F4, D4 and 
F16) were lysed in RIPA buffer (20 nM Tris-HCl pH7.4, 150 mM NaCl, 1 mM EDTA, 
1% Triton X-100, 0.5% SDS and 1 % sodium dexycholate) and incubated on ice for 
20 minutes. Samples were homogenised with scalpel tearing/vortexing prior to high 
pulse centrifuging for 3 minutes at 4°C followed by additional homogenisation with a 
needle. The liquid sample was recovered and the appropriate volume of 6 x gel 
sample buffer added. Samples were then heated at 95°C for 5 minutes and stored at 
-80°C. Cells were lysed for 10 min in NP-40 lysis buffer (15) and clarified by 
centrifugation at 13,000 x g for 10 min. Proteins were resolved by SDS-PAGE as 
previously described (15) and immunoblotted with the relevant antibodies. For 
immunoprecipitation clarified cell lysates were incubated with anti-GFP antibody 
overnight at 4°C followed by 1 h incubation with Protein G Sepharose beads (GE 
Healthcare). The immune complexes were washed and resuspended in 2X SDS 
loading buffer. Proteins were resolved by SDS-PAGE as previously described (15) 
and immunoblotted with the relevant antibodies. GFP-TRAP (Clontech) was 
performed according to the protocol.  
 
 
Palmitoylation Assay  
The protein under investigation was immunoprecipitated from cell lysates. The 
isolated beads were then incubated with 20-50 mM N-Ethylmaleimide (NEM) to block 
all cysteine residues for 2 h-overnight at 4˚C. This incubation Beads were washed to 
remove excess NEM and then incubated in palmitoylation buffer 1 (1M 
hydroxylamine, 50 mM Tris, 150 mM NaCl, 5 mM EDTA, 0.2% Triton X-100, pH7.4) 
to remove any palmitate bound to cysteine residues for 2 h at room temp. 
Palmitoylation buffer 1 was then removed and substituted with palmitoylation buffer 2 
(4 µM BMCC-Biotin, 50 Mm Tris, 150 mM NaCl, 5 mM EDTA, 0.2% Triton x-100, pH 
6.2) for 2 h at room temperature. Biotin-BMCC will bind the previously S-acylated 
protein residues and the resulting lysates can be processed by western blotting. The 
level of protein palmitoylation is detected with streptavidin-HRP probing for the 
biotin-BMCC signal. The control for the palmitoylation assay is a duplicate of the 
lysate which has not been incubated with hydroxylamine. The absence of a signal in 
the control confirms that in the hydroxylamine positive lysate a biotin-BMCC 
palmitate switch has occurred. Following incubation beads were thoroughly washed 
before adding gel sample buffer and storing at -20˚C. 
 
RT-PCR 
Total RNA was isolated from cells using the RNeasy kit (Qiagen). Reverse 
transcription was carried out with the High Capacity RNA-to-cDNA kit (Applied 
Biosystems). The cDNA obtained from the RT reaction was then used in a PCR with 
REDTaq ReadyMix PCR Reaction Mix with MgCl2 (Sigma-Aldrich). RT-PCR 
products were resolved by electrophoresis in 1.5% ethidium bromide-stained 
agarose gels. 
 
Immunohistochemistry  
Prostate cancer tissues were obtained through the U-CAN project (16) (www.u-
can.uu.se). The tissue microarray (TMA) cohort was constructed from formalin fixed 
paraffin embedded tumors as previously described (17). Immunohistochemistry and 
slide scanning were performed at the Swedish SciLifeLab facilities (17). Primary 
antibodies were diluted in UltraAb Diluent (Thermo Fisher Scientific), and applied to 
the slides for 30 min at room temperature. The slides were further incubated with the 
secondary reagent (anti-rabbit/mouse horse reddish peroxidase-conjugated 
UltraVision; Thermo Fisher Scientific) for 30 min at room temperature. Following the 
washing steps, the slides were developed for 5 min using the avidin-biotin 
peroxidase staining technique (Vector Elite; Vector Laboratories, Burlingame, CA, 
USA) using 3,3-diaminobenzidine as the substrate. Slides were counterstained in 
Mayers hematoxylin (01820, Histolab) for 5 minutes using the Autostainer XL 
(Leica), and then rinsed in lithium carbonate water (diluted 1:5 from saturated 
solution) for 1 minute. The slides were dehydrated in graded ethanol and lastly 
coverlipped (PERTEX, Histolab) using an automated glass coverslipper (CV5030, 
Leica). The slides were scanned using the automated scanning system Aperio XT 
(Aperio Technologies). Scoring of TMAs was conducted by pathologists, a specialist 
registrar in Medical Oncology and a Scientist based at Guy’s and St Thomas’ 
Hospital, King’s College London and the University of Bologna. FASN, RhoU and 
Cdc42 staining was dichotomised and assessed as negative/low and high intensity.  
 
The Cancer Genome Atlas analysis  
Normalised RSEM values from RNAseq for 51 Gleason 6, 171 Gleason 7 (3+4), 117 
Gleason 7 (4+3), 67 Gleason 8, 141 Gleason 9 and 4 Gleason 10 samples obtained 
from The Cancer Genome Atlas (TCGA) (18). Gleason 6 (3+3) and 7(3+4) patients 
were combined to form Low Gleason score group and Gleason 7 (4+3) – 10 were 
combined into a High Gleason score group. T-test to compare groups was carried 
out using R3.3(19).  
  
Statistical Analysis  
Data presented is mean +/- standard deviation unless stated otherwise.  Statistical 
significance was determined by either ANOVA tukey test or Student’s t-test. ** 
p<0.01, ***p<0.001 where the mean is the average of three independent 
experiments. All data met the statistical requirements for selected test. Sample size 
was determined by previous experimental datasets for comparison.  
 
  
Results 
FASN depletion suppresses migration and invasion  
To explore the relationship between FASN and cell migration we reduced FASN 
expression in PC3 and 1542-CPTX cells (subsequently referred to as 1542 cells) 
using ShRNAi technology. 1542 cells were derived from a radical prostectomy and 
represent cells within the primary tumour with migratory potential (13). These cells 
express c-Met (Fig. S1A) and have a migratory response to HGF (Fig. S1B). PC3 
cells are an established model of HGF-induced migration (20). Stable FASN 
knockdown 1542 and PC3 cells were generated by lentiviral transfection (Fig. 1A 
and Fig. S1C) using two different siRNA sequences (A3 and A4). Whilst the focus of 
our investigation was migration we tested cellular proliferation since some migration 
assays are not suitable for populations with significant differences in proliferation 
rates. Consistent with previous reports (6) we found a reduced proliferation rate (Fig. 
S1D) but no evidence for apoptosis (see movies 1 and 2). We therefore used a direct 
imaging cell migration assay which is independent of proliferation. We detected a 
significant reduction in HGF- stimulated mean cell migration in all the FASN shRNA 
cell lines compared to control (Fig. 1B, Fig. 1C and Fig. S1E). To complement our 
shRNA study we also utilised pharmacological inhibition of FASN activity, using two 
well characterised FASN inhibitors (C75 and Orlistat) in our migration assay. In 
agreement with our shRNA results, inhibition of FASN activity also significantly 
supressed HGF-induced migration (Fig. 1D, Fig. S1F). It has been previously 
reported that FASN depletion reduces c-Met expression (9) and thus our data might 
reflect a loss of HGF signalling in our FASN depleted cells. However although we did 
detect a modest reduction in c-Met expression; our cells retained a normal 
biochemical response to HGF (Fig. S2A and Fig. S2B). Furthermore, in a HGF-
independent inverted invasion assay FASN ShRNA cells were again unable to 
migrate/invade the collagen matrix when compared with control cells (Fig. 1E and 
1F and Fig. S1G).  
 
FASN depletion increases cell adhesion  
Our data supports a critical role for FASN activity during cell migration. A common 
reason for a reduction in migration speed is an increase in adhesion of cells to the 
underlying matrix. We therefore tested the adhesion of FASN ShRNA 1542 cells to 
specific matrix. We observed a significant increase in cell adhesion in the FASN 
depleted population both on matrigel and collagen I (Fig. 2A and 2B). Furthermore, 
detailed analysis revealed that FSAN depleted cells were more likely to display 
prominent peripheral paxillin associated adhesions (Fig. 2C&D). Similar results were 
obtained in FASN depleted PC3 cells (Fig. S2C). Indeed, even when control cells 
exhibited detectable peripheral adhesions (Figure 2C*) the adhesions in FASN 
depleted cells were longer (Fig.2E).  Importantly, addition of exogenous palmitate 
rescued the adhesion phenotype (Fig. 2C, D and E), whilst having no impact on 
FASN expressing cells (Fig.S2D) demonstrating the dependence of cells on 
palmitate to manage optimal matrix adhesion. 
Increased adhesion of cell to matrix can either be explained by increased adhesion 
forming activity or a decrease in the ability of cells to turnover adhesions that are 
already formed. We have previously shown that the level of  paxillin phosphorylation 
at serine 272 (S272) is a direct measure of adhesion turnover (15), where low 
paxillin S272 levels are indicative of reduced adhesion turnover leading to more and 
larger adhesions.  We now find that paxillin S272 phosphorylation is significantly 
reduced in the FASN knockdown cells (Fig. 2F). Furthermore addition of exogenous 
palmitate raises paxillin S272 phosphorylation in FASN depleted cells back to control 
levels (Fig. S2E); thus demonstrating a direct link between de novo lipogenesis and 
cell adhesion turnover.  
 
FASN depletion reduces RhoU palmitoylation  
Our previous work, in breast cancer, reported that depletion of RhoU expression led 
to increased peripheral adhesions and reduced paxillin S272 phosphorylation; the 
same phenotype observed here in FASN knockdown cells (15). We therefore 
reasoned that perturbation of RhoU might be directing the FASN phenotype. 
However, FASN depletion did not change total RhoU protein levels (Fig. 3A). We 
thus began to consider whether post-translational modification of RhoU was 
impaired. RhoU is thought to be targeted to membranes by palmitoylation (21) and 
we confirmed that RhoU can be palmitoylated (Fig. 3B). Given that exogenous 
palmitate can rescue the adhesion phenotype we hypothesised that perhaps RhoU 
palmitoylation was under pressure in FASN depleted cells because there was a lack 
of palmitate. In support of this hypothesis in cells overexpressing both FASN and 
RhoU we detected an increase in RhoU palmitoylation (Fig. 3C) whilst GFP-RhoU 
palmitoylation was reduced in FASN knockdown cells (Fig. 3D&E). Most importantly, 
palmitoylation of endogenous RhoU was also significantly decreased in FASN 
depleted cells (Fig. 3F and Fig.S3A). These data strongly suggest that FASN activity 
can influence RhoU palmitoylation. Interestingly we did not detect modulation of Rac 
palmitoylation (Fig. S3B) nor changes in total Rac levels (Fig. S3C), suggesting that 
RhoU is particularly sensitive to a reduction in available palmitate in a FASN 
knockdown background. These data suggest that palmitoylation of RhoU is an 
important step in adhesion turnover. To confirm this hypothesis we demonstrated 
that depletion of RhoU leads to the same changes in adhesion dynamics in prostate 
cancer cells (Fig. 3G) and then we tested whether a RhoU mutant that cannot be 
palmitoylated (22) could rescue the RhoU knockdown phenotype. We found that 
expression of a siRNA resistant RhoU-Wildtype could rescue mean focal adhesion 
length in cells with depleted RhoU whilst expression of siRNA resistant RhoU-PALM 
(palmitoylation mutant) could not rescue the adhesion phenotype (Fig. 3G).   
 
FASN depletion reduces cell spread area via modulation of Cdc42 expression 
FASN knockdown cells also exhibited a reduction in spread area (Fig. 4A&B and 
Fig. S4A) whilst overexpression of GFP-FASN increased cell spread area (Fig. 
4C&D). Moreover, we again found that addition of exogenous palmitate to FASN 
depleted cells rescued cell spread area to control levels (Fig. 4E). RhoU has not 
been linked to cell spread area but another Rho family GTPase Cdc42, that can also 
be modulated by palmitoylation, has been associated with the regulation of cell 
spread area (23).  We therefore hypothesised that Cdc42 might be impacted by loss 
of FASN. In contrast to RhoU we detected a significant loss of Cdc42 protein 
expression in our FASN depleted cells (Fig. 5A and Fig. S4B). Moreover, we could 
reproduce the loss of Cdc42 protein levels by treating cells with the FASN activity 
inhibitor C75 (Fig. 5B and Fig. S4C). Cells can express two variants of Cdc42, one 
which can only be palmitoylated (referred to here as Cdc42-PALM) or one that is 
prenylated (referred to here as canonical). We assumed that Cdc42-PALM was 
expressed by our cells and lost in the FASN depleted cells. However to our surprise, 
using PCR primers specific to the two variants, we discovered that our prostate cell 
lines do not generate Cdc42-PALM mRNA rather they exclusively express canonical 
Cdc42 and the level of canonical Cdc42 mRNA is not reduced by FASN depletion 
(Fig. 5C and Fig. S4D).  
 
RhoU regulates canonical Cdc42 protein levels  
Given that canonical Cdc42 is not palmitoylated we sought to understand how loss of 
FASN expression could impact on canonical Cdc42 at the protein level. We 
speculated that perhaps there existed a complex between RhoU and Cdc42 given 
that other Rho Family GTPases interact (24) and found that RhoU and Cdc42 can be 
immunoprecipitated from cells (Fig. 6A). We then tested Cdc42 expression levels in 
RhoU depleted cells. Excitingly we detected a dramatic loss of Cdc42 expression in 
RhoU depleted cells (Fig. 6B). Thus suggesting that Cdc42 protein levels are very 
sensitive to modest reductions in RhoU expression. Moreover, using a global 
inhibitor of palmitoyltransferase activity (Fig. 6C) we confirmed that canonical Cdc42 
protein levels are dependent on protein palmitoylation. Thus RhoU and Cdc42 are 
particularly vulnerable to a reduction in intracellular palmitate levels following FASN 
suppression. Overexpression of canonical Cdc42 in 1542 FASN knockdown cells 
rescued our cell spread area phenotype (Fig. 6D&E) supporting a specific role for 
canonical Cdc42.   
 
 
FASN, RhoU and Cdc42 expression is increased in high gleason grade 
prostate cancer 
Our results suggest that levels of RhoU and Cdc42 expression in prostate cancer 
cells are associated and could be correlated with disease progression. Using data 
held in The Cancer Genome Atlas (TCGA) we found that there is a highly significant 
difference in RhoU expression and a trend towards significant difference in Cdc42 
expression when comparing mRNA signals in low and high Gleason score samples 
(Fig 7A). We next evaluated expression in a panel of prostate cancer patient 
samples from the U-CAN resource (16). The cohort for this study consisted of 85 
men (mean age 67.18) who had undergone a radical prostatectomy. The majority of 
these men had a Gleason score of 7 (60.00% 51/85), whilst the minority had a 
Gleason score of 5 (2.35% 2/85) (TableS1). Tissue was stained for FASN, RhoU and 
Cdc42 expression and the comparative intensity of staining recorded. Univariate 
analysis revealed that relative to benign tissue, both DG and HG (Dominant 
Gleason-DG and Highest Gleason-HG) cancerous tissue types were significantly 
associated with an increase in the expression of FASN, RhoU, and Cdc42 (Fig. 7B 
and TableS2). Taken together this analysis strongly suggests the involvement of 
RhoU and Cdc42 in prostate cancer progression.  
 
Discussion 
Currently, there is mounting evidence which suggests that FASN is involved in 
prostate cancer progression, however little is known about the pathways or proteins 
that act downstream of FASN (25).  
This study focussed on investigating whether FASN was involved in regulating 
proteins that drive cell migration. FASN depletion reduced the migratory capability of 
prostate cancer cells in both 2D migration and 3D invasion assays. The migration 
defect was also phenocopied by pharmacological inhibition of FASN activity, thus 
providing compelling evidence that loss of generation of palmitate rather than loss of 
non-canonical scaffolding functions are likely responsible for the observed 
phenotypes. Whilst FASN has previously been reported to be important in the 
migration of several different cancers (25) this is the first study to focus directly on 
FASN driven migration and invasion in advanced prostate cancer cell models.  
 
Previous work has identified a relationship between FASN and the androgen 
receptor (26). However, the cells studied here represent androgen independent 
disease and so we sought an alternative explanation for the observed phenotypes. 
Our exploration of the molecular mechanisms underlying our FASN deletion 
phenotypes have revealed that a lack of palmitate availability has significant impacts 
on the ability of some RhoGTPases to function in cells.  We discovered that 
depletion of FASN in prostate cancer leads to a decrease in the palmitoylation of the 
atypical Rho GTPase RhoU. The silencing of RhoU has been shown to reduce the 
migratory capacity of PC3 and MDA-MB-231 breast cancer cells (15, 27). However, 
nothing is currently known about how reduced palmitoylation affects RhoU-induced 
cell migration. We propose that a reduction in RhoU palmitoylation leads to a loss of 
paxillin S272 phosphorylation which is required for adhesion disassembly (15). This 
is supported by the observation that addition of exogenous palmitate rescued the 
adhesion phenotype in FASN knockdown prostate cancer cells. Thus, it could be 
speculated that the exogenous palmitate taken up by the cells has been specifically 
utilised to restore RhoU palmitoylation and subsequent paxillin phosphorylation. It is 
currently unclear how RhoU mediates paxillin phosphorylation, however it has been 
suggested to be via PKC, PKA (protein kinase A), PKG (protein kinase G) or myosin 
light chain kinase (15). Our findings support recent studies demonstrating that 
cancer cells expressing high levels of the FA receptor CD36 show high metastatic 
potential (12). CD36 facilitates the uptake of exogenous palmitate and thus would 
drive the same pathways we have identified here. Indeed, we would suggest that 
RhoU activity might be central to the molecular mechanism underlying these in vivo 
observations (12).  
 
It is interesting that we did not detect impacts on Rac palmitoylation. We would 
postulate that the majority of Rac is prenylated and so a reduction in palmitate 
availability is not as impactful. Prenylated Rac may be correctly localised and more 
readily able to access any residual intracellular pools of palmitate. We anticipate that 
knockdown of FASN will not lead to a complete loss of intracellular palmitate but 
rather a significant reduction which is not compensated fully by exogenous palmitate 
unless we add palmitate in excess. This is supported by our finding that adding 
excess palmitate to the cell medium rescued the cell behaviour phenotypes.  
 
Whilst Rac was not impacted, this study also identified Cdc42, as directly affected by 
FASN depletion. FASN knockdown cells were smaller in size and migrated at a 
reduced speed when compared to their control counterparts. These same 
phenotypes have previously been reported in Cdc42 knockdown PC3 cells (28). We 
detected in the FASN depleted cells a significant decrease in Cdc42 protein levels; 
with no concomitant reduction in mRNA levels. Interestingly, pharmacological 
inhibition of FASN also decreased Cdc42 protein expression, suggesting that again 
lack of palmitate availability was core to the reduction of Cdc42 protein. We 
speculated that in FASN depleted cells the palmitoylated splice variant of Cdc42 was 
being affected as a result of reduced palmitate biosynthesis. Indeed, global blockage 
of palmitoylation also decreased Cdc42 protein levels. However, palmitoylated 
Cdc42 mRNA was un-detectable in both cell lines. Therefore this data rather 
suggests that in these prostate cell lines the canonical prenylated isoform of Cdc42 
is being affected in response to the loss of FASN activity. In support of this 
hypothesis canonical Cdc42 re-expression partially rescued the morphological defect 
seen in FASN knockdown cells. These finding lead us to speculate that perhaps 
there was a link between RhoU and Cdc42 where modulation of RhoU palmitoylation 
might account for the destabilisation of Cdc42 protein. Indeed, we found that 
depletion of RhoU expression lead to a significant reduction in Cdc42 protein 
expression. Moreover, RhoU and Cdc42 could be co-immunoprecipitated. Whilst not 
a direct evidence of interaction we would postulate that RhoU and Cdc42 might 
heterodimerise. It has been shown that several Rho GTPases including Cdc42, 
RhoA and Rac1 are able to homodimerize (24); perhaps the considerable sequence 
homology between RhoU and Cdc42 allows heterodimerisation. Alternatively, these 
two proteins may be intrinsically linked in a larger protein complex required for 
Cdc42 stability.  
 
To test the clinical significance of our findings we analysed FASN, RhoU and Cdc42 
in prostate cancer and adjacent benign tissue a cohort of 85 men who underwent a 
radical prostatectomy. Immunohistochemical staining revealed that the increased 
expression of FASN, RhoU and Cdc42 was associated with prostate cancer 
agressiveness. It is important that both RhoU and FASN expression are increased to 
deliver an increase in the potential for higher levels of palmitoylated RhoU. Higher 
levels of palmitoylated RhoU would be predicted to lead to increased levels of Cdc42 
stability and thus expression; and this is what we observe in patient tissue. In the 
absence of increased FASN expression we would predict that, despite high RhoU 
expression, the levels of Cdc42 expression would be unchanged.  
 
In conclusion this study provides evidence that an increased level of FASN 
expression leads to both a proliferative and invasive advantage. Our results suggest 
that the invasive advantage is directly related to the increased availability of de novo 
synthesised palmitate which supports RhoU palmitoylation mediated cell adhesion 
turnover and promotes canonical Cdc42 stabilisation. Together these activities help 
to drive prostate cancer cell invasion. Thus blocking the activity of FASN in prostate 
cancer cells is an attractive therapeutic pathway.   
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 Figure Legends 
 
Figure 1: Loss of FASN expression impairs migration and invasion. A) cell 
lysates were immunoblotted for FASN and loading control HSP90. Densitometry 
analysis was performed and relative quantification of FASN levels calculated. B) 
cells were seeded on matrigel, serum starved, stimulated with 10 ng/ml HGF and 
imaged for 16 h at 5 minute intervals. Migration plots of each cell line (60 cells per 
condition). C) Mean (+/- SEM) speed of migration D) 1542 cells were seeded on 
matrigel, serum starved, incubated with DMSO, C75 or orlistat and then stimulated 
with 10 ng/ml HGF. Images were taken and processed as described above (C) Mean 
(+/- SDev). 60 cells per condition E) cells were overlaid with a type I collagen for 24 
hours. Cells were fixed and stained with Hoechst. Cells at 0 μm (bottom) and 50 
μm.were imaged F) Percentage of cells invading over 50 μm. All data represents the 
mean values ± SDev from three independent experiments. Statistical significance 
was determined by Student’s t-test. ** p<0.01, ***p<0.001 
 
Figure 2: Loss of FASN expression modulates cell adhesion dynamics.  
A) cells were seeded on matrigel (A) or type I collagen for 1 h (B). Absorbance 
measurements at OD540. C) 1542 shControl, 1542 shFASN A3, BSA-treated 1542 
shFASN A3, BSA-Palmitate (50uM) treated 1542 shFASN A3 cells were incubated 
for 1 h fixed and stained for paxillin. White arrows indicate magnified area. * 
indicates a cell with prominent paxillin associated adhesions. D) Percentage of cells 
with visible peripheral paxillin positive adhesions. 90 cells counted per condition E) 
Mean adhesion length. >10 adhesions counted per cell. All data represents the 
mean adhesion length per cell ± SDev accumulated from three independent 
experiments. Statistical significance was determined by an ANOVA Tukey test * 
p<0.05, ** p<0.01, ***p<0.001. . n.s= not significant. F) Cell lysates were probed for 
paxillin, S272 phospho-paxillin and HSP90 as a loading control. Densitometry 
analysis was performed and relative quantification of paxillin, S272 phospho-paxillin 
levels calculated. All data represents the mean values ± SDev from three 
independent experiments. Statistical significance was determined by Student’s t-test. 
*p<0.05, **p<0.01. n/s= not significant. Bar= 10 μM.  
 
Figure 3: Palmitoylation of RhoU is impaired in a FSAN depleted background. 
A) Cell lysates were probed for RhoU and HSP90 as a loading control. B) HEK293 
cells were transfected with GFP-RhoU. Cell lysates were assayed for protein 
palmitoylation. Biotinylated-BMCC modified samples (palmitoylation positive) were 
detected using streptavidin-HRP. Omission of hydroxylamine (Hydroxyl) acts as a 
negative control. Cell lysates were probed with anti-GFP and anti-HSP90. C) 
HEK293 cells were transfected with GFP-RhoU in the absence/presence of Flag-
FASN as indicated. Cell lysates were assayed for protein palmitoylation as described 
above.  Cell lysates were probed with anti-FASN, anti-GFP and anti-HSP90. D)  cells 
were transfected with GFP-RhoU. Whole cells lysates were assayed for protein 
palmitoylation as described above. Cell lysates were probed with anti-FASN, anti-
GFP and anti-HSP90. E) Quantification of RhoU palmitoylation in (D). F) RhoU was 
immunoprecipitated using an in-house anti-PAK4 antibody (23). A palmitoylation 
assay was conducted on immunoprecipitated protein as described above. In all 
above densitometry analysis was performed and relative levels calculated. All data 
represents the mean values ± SDev from three independent experiments. Statistical 
significance was determined by Student’s t-test. *p<0.05, **p<0.01. G) 1542 cells 
were treated as indicated with control or RhoU siRNA. Cells were than transfected 
with HA-tagged RhoU-WT or RhoU-PALM (mutant that cannot be palmitoylated). 
Cells were then fixed and stained for paxillin and expression of HA-tagged protein. 
Mean adhesion length was calculated and statistical significance determined by an 
ANOVA Tukey test. p< 0.001.   
 
Figure 4: Loss of FASN expression reduces cell spread area.  
A) cells were seeded on Matrigel, fixed and stained for phalloidin. B) Mean cell area 
(90 cells per condition). C) 1542 cells transfected with either GFP- alone or GFP-
FASN were seeded on Matrigel. Cells were stained with DAPI and Phalloidin. D) 
Mean cell area (90 cells per condition). E) cells were seeded onto matrigel in the 
absence or presence of BSA /BSA conjugated-palmitate 50 μM as indicated. Cells 
were incubated for one hour fixed and stained for F-actin. Mean cell area (90 cells 
per condition). In all above data represents the mean values ± SDev from three 
independent experiments. Statistical significance was determined by an ANOVA 
Tukey test * p<0.05, ** p<0.01, ***p<0.001.  n.s= not significant Scale bar = 10 μm. 
 
Figure 5: Loss of FASN activity leads to concomitant loss of canonical Cdc42 
expression.  
A) cell lysates were probed for Cdc42 and HSP90 as a loading control. 
Quantification of protein expression was then determined by densitometry analysis.  
B) 1542 cells were treated with DMSO or C75 25 μM for 24 hours before lysing. Cell 
lysates were probed for Cdc42 and HSP90 as a loading control. In all above data 
represents the mean values ± SDev accumulated from three independent 
experiments. Statistical significance was determined by Student’s t-test. *p<0.05, 
**p<0.01, ***p<0.001. C) cDNA was generated and used in a PCR reaction. PCR 
primers designed to the prenylated isoform of Cdc42 or the palmitoylated isoform of 
Cdc42 were used. cDNA plasmids containing either the prenylated or palmitoylated 
isoform were used as controls. β-actin primers were used as a loading control. 
 
Figure 6: Cdc42 expression is dependent on RhoU.  
A) HEK293 cells were co-transfected with either GFP-Cdc42 and HA-RhoU or GFP  
and HA-RhoU. Cells were lysed and a GFP-TRAP was performed. GFP-TRAP 
samples and input lysates were probed for GFP and HA simultaneously. B) 1542 
cells were transfected with siControl and siRhoUpool for 48 hours (left panel) and 
1542 cells were transfected with siControl and siRhoU single oligos (#3 and #4) from 
pool for 48 hours (right panel). Cell lysates were probed for RhoU, Cdc42 and 
HSP90 as a loading control. Quantification of left hand panel C) Palmitate 
incorporation was inhibited by treating the cells with 2-Bromopalmitate (2BP) 100 μM 
for 24 hours. Cell lysates were probed for RhoU, Cdc42 and HSP90 as a loading 
control. D) Cells transfected with GFP or GFP-Cdc42 cells were seeded onto 
matrigel. Cells were fixed and stained for F-actin (grey). E)  ImageJ was used to 
calculate the cell area (60 cells per condition). All above quantification of protein 
expression was determined by densitometry analysis. Data represents the mean 
values ± SDev from three independent experiments. Statistical significance was 
determined by an ANOVA Tukey test * p<0.05, ** p<0.01, ***p<0.001. n.s= not 
significant. Bar= 10 μM.   
 
Figure 7: High expression of FASN, RhoU and Cdc42 is detected in human 
prostate cancer.  A) Normalised RSEM expression levels of MKI67 and RHOU for 
all samples available in TCGA. The expression of both genes increases with 
Gleason Score and are significantly different (t-test, p<0.00005) when comparing low 
Gleason score samples (Gleason 6 and Gleason 7 (3+4) with high Gleason score 
(Gleason (4+3) to Gleason 10). B) Baseline characteristics of radical prostatectomy 
patients included in the UCAN database. SD= Standard deviation, IQR= Interquartile 
range. C) Representative immunohistochemistry for FASN, RhoU, and Cdc42, in 
benign tissue and prostatic adenocarcinoma (dominant and highest Gleason): 
Images for each protein were taken from the same core on the same TMA. D) 
Univariate odds ratios (OR) with 95% confidence intervals (CI) to predict abnormal 
expression levels of FASN, RhoU, Cdc42 based on prostate tissue type (i.e. 
dominant and highest Gleason score tissue versus benign tissue).  
 
Movie 1 = Control 1542 cells on matrigel  
Movie 2 = ShRNA A3 1542 cells on matrigel  
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